Biggest Manufacturer， R racemic， LOXO-195 （1350884-56-8 ） more than 20g in stock

EOS med chem is the only manufacturer that provides excellent quality chemistry products and services at affordable rates. The experts working here are highly trained to handle these chemicals used in the creation of medicines used for treating various life-threatening diseases. We are into the manufacturing of chemical products after doing a deep research for the same.

EOS team of experts holds the work experience of more than ten years, and therefore we can assure you about the quality and superiority of the products and services we offer to all our valued clients around the globe. At present, this organization is listed among the most leading pharmaceutical suppliers around the world. We always supply products keeping the affordability in mind.

2018 Korea CPHI, C30

LOXO-195 is a potent and selective TRK inhibitor capable of addressing potential mechanisms of acquired resistance that may emerge in patients receiving larotrectinib (LOXO-101) or multikinase inhibitors with anti-TRK activity. LOXO-195 demonstrated potent inhibition of TRK fusions, including critical acquired resistance mutations, in enzyme and cellular assays, with minimal activity against other kinases. In diverse TRK fusion mouse models, LOXO-195 inhibited phospho-ERK and caused dramatic tumor growth inhibition, superior to first generation TRK inhibitors, without significant toxicity

LOXO-195 , CAS#1350884-56-8, HNMR, HPLC 99%+, LCMS, COA, MSDS and ROS, more than 20G in stock, pls check:

Name:LOXO-195

CAS#: 1350884-56-8

 Formula: C20H21FN6O 

Exact Mass: 380.1761 

Molecular Weight: 380.4274 

Elemental Analysis: C, 63.14; H, 5.56; F, 4.99; N, 22.09; O, 4.21

Appearance: white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Related CAS #: 2097002-61-2   2097002-59-8 (RS-isomer)   1350884-56-8 (R racemic)    

Synonym: LOXO-195; LOXO 195; LOXO195.

IUPAC/Chemical Name: (13E,14E,22R,6R)-35-fluoro-6-methyl-7-aza-1(5,3)-pyrazolo[1,5-a]pyrimidina-3(3,2)-pyridina-2(1,2)-pyrrolidinacyclooctaphan-8-one

InChi Key: OEBIHOVSAMBXIB-SJKOYZFVSA-N

InChi Code: InChI=1S/C20H21FN6O/c1-12-4-5-16-14(9-13(21)10-22-16)17-3-2-7-26(17)18-6-8-27-19(25-18)15(11-23-27)20(28)24-12/h6,8-12,17H,2-5,7H2,1H3,(H,24,28)/t12-,17-/m1/s1

SMILES Code: FC1=CN=C(CC[C@@H](C)NC(C2=C3N(C=CC4=N3)N=C2)=O)C([C@@H]5N4CCC5)=C1

Reference：

Can·cer, redefined 

Lisa M. Jarvis 

C&EN Global Enterp, 2017, 95 (27), pp 26–30 

Publication Date (Web): July 3, 2017 (Article) 

DOI: 10.1021/cen-09527-cover

Biggest Manufacturer，Valbenazine（1025504-45-3） and Intermediates.

EOS med chem is the only manufacturer that provides excellent quality chemistry products and services at affordable rates. The experts working here are highly trained to handle these chemicals used in the creation of medicines used for treating various life-threatening diseases. We are into the manufacturing of chemical products after doing a deep research for the same.

EOS team of experts holds the work experience of more than ten years, and therefore we can assure you about the quality and superiority of the products and services we offer to all our valued clients around the globe. At present, this organization is listed among the most leading pharmaceutical suppliers around the world. We always supply products keeping the affordability in mind.

2018 Korea CPHI, C30

EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
WEB: www.eosmedchem.com
EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com  TEL: 0086-531-69905422
GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.

1.

Valbenazine，CAS#1025504-45-3, HNMR, HPLC 99%+, LCMS, COA, MSDS and ROS, more than 32KG in stock, pls check:

Name:Valbenazine

CAS#: 1025504-45-3

Formula: C24H38N2O4 

Exact Mass: 418.2832 

Molecular Weight: 418.578 

Elemental Analysis: C, 68.87; H, 9.15; N, 6.69; O, 15.29

Appearance: white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

2. 

Valbenazine Intermediates:

1. Valbenazine Intermediate:(2-Acetyl-4-Methylpentyl)trimethylammonium Iodide, 

Cas#1069-62-1, 

We have more than 46kg in stock, assay 99% in GMP plant, C-GMP standard,

now COA, NMR, HPLC, MS is ok.

2. Valbenazine Intermediate:6,7-Dimethoxy-3,4-dihydroisoquinoline

Cas#3382-18-1 

We have more than 53kg in stock, assay 99% in GMP plant, C-GMP standard,

now COA, NMR, HPLC, MS is ok.

3. Valbenazine Intermediate:3-isobutyl-9,10-dimethoxy-3,4,6,7-tetrahydro-1H-pyrido[2,1-a]isoquinolin-2(11bH)-one

Cas#718635-93-9

We have more than 47kg in stock, assay 99% in GMP plant, C-GMP standard,

now COA, NMR, HPLC, MS is ok.

4. Valbenazine Intermediate:2H-Benzo[a]quinolizin-2-one, 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-, (3R,11bR)-

Cas#1026016-83-0

We have more than 35kg in stock, assay 99% in GMP plant, C-GMP standard,

now COA, NMR, HPLC, MS is ok.

5. Valbenazine Intermediate:[2R-(2a,3b,11bb)]-1,3,4,6,7,11b-Hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-ol

Cas#85081-18-1

We have more than 54kg in stock, assay 99% in GMP plant, C-GMP standard,

now COA, NMR, HPLC, MS is ok.

REFERENCES:

1: O'Brien CF, Jimenez R, Hauser RA, Factor SA, Burke J, Mandri D, Castro-Gayol JC. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. Mov Disord. 2015 Oct;30(12):1681-7. doi: 10.1002/mds.26330. Epub 2015 Sep 8. PubMed PMID: 26346941; PubMed Central PMCID: PMC5049616.

2: Barquero N. Valbenazine for the treatment of tardive dyskinesia. Drugs Today (Barc). 2016 Dec;52(12):665-672. doi: 10.1358/dot.2016.52.12.2570977. Review. PubMed PMID: 28276538.

3: Müller T. Valbenazine granted breakthrough drug status for treating tardive dyskinesia. Expert Opin Investig Drugs. 2015 Jun;24(6):737-42. doi: 10.1517/13543784.2015.1029573. Epub 2015 Mar 25. PubMed PMID: 25809133.

4: Grigoriadis DE, Smith E, Hoare SRJ, Madan A, Bozigian H. Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites. J Pharmacol Exp Ther. 2017 Jun;361(3):454-461. doi: 10.1124/jpet.116.239160. Epub 2017 Apr 12. PubMed PMID: 28404690.

5: Meyer JM. Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia. CNS Spectr. 2016 Dec;21(S1):13-24. doi: 10.1017/S1092852916000730. Review. PubMed PMID: 28044943.

6: Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016 Dec;17(18):2461-2470. Review. PubMed PMID: 27819145.

7: Citrome L. Emerging pharmacological therapies in schizophrenia: what's new, what's different, what's next? CNS Spectr. 2016 Dec;21(S1):1-12. doi: 10.1017/S1092852916000729. Review. PubMed PMID: 28044942.

8: Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, Burke J, Liang GS, O'Brien CF. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. Am J Psychiatry. 2017 May 1;174(5):476-484. doi: 10.1176/appi.ajp.2017.16091037. Epub 2017 Mar 21. PubMed PMID: 28320223.

9: Garay RP, Citrome L, Samalin L, Liu CC, Thomsen MS, Correll CU, Hameg A, Llorca PM. Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. Expert Opin Pharmacother. 2016;17(7):921-36. doi: 10.1517/14656566.2016.1149164. Epub 2016 Feb 19. Review. PubMed PMID: 26831200.

10: Kane JM, Correll CU, Liang GS, Burke J, O'Brien CF. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder. Psychopharmacol Bull. 2017 Aug 1;47(3):69-76. PubMed PMID: 28839342; PubMed Central PMCID: PMC5546553.

11: Freudenreich O, Remington G. Valbenazine for Tardive Dyskinesia. Clin Schizophr Relat Psychoses. Summer 2017;11(2):113-119. doi: 10.3371/CSRP.OFGR.071717. Review. PubMed PMID: 28742396.

12: Correll CU, Josiassen RC, Liang GS, Burke J, O'Brien CF. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder. Psychopharmacol Bull. 2017 Aug 1;47(3):53-60. PubMed PMID: 28839340; PubMed Central PMCID: PMC5546551.

13: Kim ES. Valbenazine: First Global Approval. Drugs. 2017 Jul;77(10):1123-1129. doi: 10.1007/s40265-017-0770-9. Review. PubMed PMID: 28578484.

14: Davis MC, Miller BJ, Kalsi JK, Birkner T, Mathis MV. Efficient Trial Design - FDA Approval of Valbenazine for Tardive Dyskinesia. N Engl J Med. 2017 Jun 29;376(26):2503-2506. doi: 10.1056/NEJMp1704898. Epub 2017 May 10. PubMed PMID: 28489481.

15: Seeberger LC, Hauser RA. Valbenazine for the treatment of tardive dyskinesia. Expert Opin Pharmacother. 2017 Aug;18(12):1279-1287. doi: 10.1080/14656566.2017.1353078. Epub 2017 Aug 2. PubMed PMID: 28699794.

16: Citrome L. Valbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2017 Jul;71(7). doi: 10.1111/ijcp.12964. Epub 2017 May 12. Review. PubMed PMID: 28497864.

17: Josiassen RC, Kane JM, Liang GS, Burke J, O'Brien CF. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder. Psychopharmacol Bull. 2017 Aug 1;47(3):61-68. PubMed PMID: 28839341; PubMed Central PMCID: PMC5546552.

18: Witter DP, Holbert RC, Suryadevara U. Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients. Expert Opin Pharmacother. 2017 Jul;18(10):965-972. doi: 10.1080/14656566.2017.1323874. Epub 2017 May 8. PubMed PMID: 28443349.

19: Valbenazine (Ingrezza) for tardive dyskinesia. Med Lett Drugs Ther. 2017 May 22;59(1521):83-84. PubMed PMID: 28520698.

20: Traynor K. Valbenazine approved for treatment of tardive dyskinesia. Am J Health Syst Pharm. 2017 May 15;74(10):628-629. doi: 10.2146/news170031. PubMed PMID: 28483934.

Biggest Manufacturer，Ponesimod（854107-55-4） and Intermediates.

EOS med chem is the only manufacturer that provides excellent quality chemistry products and services at affordable rates. The experts working here are highly trained to handle these chemicals used in the creation of medicines used for treating various life-threatening diseases. We are into the manufacturing of chemical products after doing a deep research for the same.

EOS team of experts holds the work experience of more than ten years, and therefore we can assure you about the quality and superiority of the products and services we offer to all our valued clients around the globe. At present, this organization is listed among the most leading pharmaceutical suppliers around the world. We always supply products keeping the affordability in mind.

2018 Korea CPHI, C30

EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
WEB: www.eosmedchem.com
EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com  TEL: 0086-531-69905422
GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.

1.

Ponesimod, CAS#854107-55-4, HNMR, HPLC 99%+, LCMS, COA, MSDS and ROS, more than 36KG in stock, pls check:

Name:Ponesimod

CAS#: 854107-55-4

Formula: C23H25ClN2O4S 

Exact Mass: 460.12236 

Molecular Weight: 460.97 

Elemental Analysis: C, 59.93; H, 5.47; Cl, 7.69; N, 6.08; O, 13.88; S, 6.95

Appearance: white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

2. 

Ponesimod Intermediates:

1.Ponesimod Intermediate:3-(2-Methylphenyl)-2-((Z)-propylimino)thiazolidin-4-one,

Cas#854107-53-2,

We have more than 42kg in stock, assay 99% in GMP plant, C-GMP standard, 

now COA, NMR, HPLC, MS is ok.

2.Ponesimod Intermediate:3-Chloro-4-hydroxybenzaldehyde,

Cas#2420-16-8,

We have more than53kg in stock, assay 99% in GMP plant, C-GMP standard, 

now COA, NMR, HPLC, MS is ok.

References：

1: Juif PE, Hoch M, D'Ambrosio D, Dingemanse J. Biocomparison of Three Formulations of the S1P1 Receptor Modulator Ponesimod in Healthy Subjects. Drugs R D. 2015 Jun;15(2):203-10. doi: 10.1007/s40268-015-0095-7. PubMed PMID: 25939333; PubMed Central PMCID: PMC4488184.

2: Scherz MW, Brossard P, D'Ambrosio D, Ipek M, Dingemanse J. Three different up-titration regimens of ponesimod, an S1P1 receptor modulator, in healthy subjects. J Clin Pharmacol. 2015 Jun;55(6):688-97. doi: 10.1002/jcph.467. Epub 2015 Feb 10. PubMed PMID: 25612299.

3: D'Ambrosio D, Steinmann J, Brossard P, Dingemanse J. Differential effects of ponesimod, a selective S1P1 receptor modulator, on blood-circulating human T cell subpopulations. Immunopharmacol Immunotoxicol. 2015 Feb;37(1):103-9. doi: 10.3109/08923973.2014.993084. PubMed PMID: 25519470.

4: Reyes M, Hoch M, Brossard P, Dingemanse J. Effects of ethnicity and sex on the pharmacokinetics and pharmacodynamics of the selective sphingosine-1-phosphate receptor 1 modulator ponesimod: a clinical study in Japanese and Caucasian subjects. Pharmacology. 2014;94(5-6):223-9. doi: 10.1159/000368837. Epub 2014 Nov 14. PubMed PMID: 25402365.

5: Hoch M, Darpo B, Brossard P, Zhou M, Stoltz R, Dingemanse J. Effect of ponesimod, a selective S1P1 receptor modulator, on the QT interval in healthy individuals. Basic Clin Pharmacol Toxicol. 2015 May;116(5):429-37. doi: 10.1111/bcpt.12336. Epub 2014 Nov 8. PubMed PMID: 25287214.

6: Reyes M, Hoch M, Brossard P, Wagner-Redeker W, Miraval T, Dingemanse J. Mass balance, pharmacokinetics and metabolism of the selective S1P1 receptor modulator ponesimod in humans. Xenobiotica. 2015 Feb;45(2):139-49. doi: 10.3109/00498254.2014.955832. Epub 2014 Sep 4. PubMed PMID: 25188442.

7: Vaclavkova A, Chimenti S, Arenberger P, Holló P, Sator PG, Burcklen M, Stefani M, D'Ambrosio D. Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2014 Dec 6;384(9959):2036-45. doi: 10.1016/S0140-6736(14)60803-5. Epub 2014 Aug 10. PubMed PMID: 25127208.

8: Ryan C, Menter A. Ponesimod--a future oral therapy for psoriasis? Lancet. 2014 Dec 6;384(9959):2006-8. doi: 10.1016/S0140-6736(14)61039-4. Epub 2014 Aug 10. PubMed PMID: 25127207.

9: Hoch M, D'Ambrosio D, Wilbraham D, Brossard P, Dingemanse J. Clinical pharmacology of ponesimod, a selective S1P₁ receptor modulator, after uptitration to supratherapeutic doses in healthy subjects. Eur J Pharm Sci. 2014 Oct 15;63:147-53. doi: 10.1016/j.ejps.2014.07.005. Epub 2014 Jul 19. PubMed PMID: 25046167.

10: Krause A, Brossard P, D'Ambrosio D, Dingemanse J. Population pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator. J Pharmacokinet Pharmacodyn. 2014 Jun;41(3):261-78. doi: 10.1007/s10928-014-9362-4. Epub 2014 Jun 15. PubMed PMID: 24930034.

11: Olsson T, Boster A, Fernández Ó, Freedman MS, Pozzilli C, Bach D, Berkani O, Mueller MS, Sidorenko T, Radue EW, Melanson M. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1198-208. doi: 10.1136/jnnp-2013-307282. Epub 2014 Mar 21. PubMed PMID: 24659797; PubMed Central PMCID: PMC4215282.

12: Brossard P, Scherz M, Halabi A, Maatouk H, Krause A, Dingemanse J. Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: favorable impact of dose up-titration. J Clin Pharmacol. 2014 Feb;54(2):179-88. doi: 10.1002/jcph.244. Epub 2014 Jan 9. PubMed PMID: 24408162.

13: Reyes M, Brossard P, Chassard D, Hoch M, Dingemanse J. Effects of ponesimod, a selective S1P1 receptor modulator, on the pharmacokinetics of a hormonal combination contraceptive. Eur J Clin Pharmacol. 2014 Mar;70(3):287-93. doi: 10.1007/s00228-013-1625-2. Epub 2013 Dec 22. PubMed PMID: 24362488.

14: You S, Piali L, Kuhn C, Steiner B, Sauvaget V, Valette F, Clozel M, Bach JF, Chatenoud L. Therapeutic use of a selective S1P1 receptor modulator ponesimod in autoimmune diabetes. PLoS One. 2013 Oct 24;8(10):e77296. doi: 10.1371/journal.pone.0077296. eCollection 2013. PubMed PMID: 24204793; PubMed Central PMCID: PMC3811978.

15: Rey M, Hess P, Clozel M, Delahaye S, Gatfield J, Nayler O, Steiner B. Desensitization by progressive up-titration prevents first-dose effects on the heart: guinea pig study with ponesimod, a selective S1P1 receptor modulator. PLoS One. 2013 Sep 12;8(9):e74285. doi: 10.1371/journal.pone.0074285. eCollection 2013. PubMed PMID: 24069292; PubMed Central PMCID: PMC3771878.

16: Brossard P, Derendorf H, Xu J, Maatouk H, Halabi A, Dingemanse J. Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol. 2013 Dec;76(6):888-96. doi: 10.1111/bcp.12129. PubMed PMID: 23594176; PubMed Central PMCID: PMC3845312.

17: Piali L, Froidevaux S, Hess P, Nayler O, Bolli MH, Schlosser E, Kohl C, Steiner B, Clozel M. The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther. 2011 May;337(2):547-56. doi: 10.1124/jpet.110.176487. Epub 2011 Feb 23. PubMed PMID: 21345969.

Biggest Manufacturer，Talazoparib tosylate sale（1373431-65-2 ） and Intermediates.

EOS med chem is the only manufacturer that provides excellent quality chemistry products and services at affordable rates. The experts working here are highly trained to handle these chemicals used in the creation of medicines used for treating various life-threatening diseases. We are into the manufacturing of chemical products after doing a deep research for the same.

EOS team of experts holds the work experience of more than ten years, and therefore we can assure you about the quality and superiority of the products and services we offer to all our valued clients around the globe. At present, this organization is listed among the most leading pharmaceutical suppliers around the world. We always supply products keeping the affordability in mind.

  2018 Korea CPHI, C30

EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
WEB: www.eosmedchem.com
EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com  TEL: 0086-531-69905422
GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.

1.

Talazoparib tosylate sale, CAS#, HNMR, HPLC 99%+, LCMS, COA, MSDS and ROS, more than45KG in stock, pls check:

Name:Talazoparib tosylate sale

CAS#: 1373431-65-2

Formula: C26H22F2N6O4S 

Exact Mass: 

Molecular Weight: 552.5568 

Elemental Analysis: C, 56.52; H, 4.01; F, 6.88; N, 15.21; O, 11.58; S, 5.80

Appearance: white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

2. 

Talazoparib tosylate sale Intermediates:

1. Talazoparib tosylate sale Intermediate:4-Amino-6-fluoro-3H-isobenzofuran-1-one

Cas#1207453-91-5

we have more than 55kg in stock, assay 99% in GMP plant, C-GMP standard,

now COA, NMR, HPLC, MS is ok.

2. Talazoparib tosylate sale Intermediate:(E)-6-fluoro-4-((4-fluorobenzylidene)amino)isobenzofuran-1(3H)-one

Cas#1620153-74-3

we have more than 50kg in stock, assay 99% in GMP plant, C-GMP standard,

now COA, NMR, HPLC, MS is ok.

3. Talazoparib tosylate sale Intermediate:2-Methyl-2H-[1,2,4]triazole-3-carbaldehyde

Cas#99651-37-3

we have more than 65kg in stock, assay 99% in GMP plant, C-GMP standard,

now COA, NMR, HPLC, MS is ok.

4. Talazoparib tosylate sale Intermediate:Ethyl7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate

Cas#1207454-57-6

we have more than 54kg in stock, assay 99% in GMP plant, C-GMP standard,

now COA, NMR, HPLC, MS is ok.

5. Talazoparib tosylate sale Intermediate:Ethyl (2S,3S)-7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate

Cas#1373431-65-2 

we have more than 63kg in stock, assay 99% in GMP plant, C-GMP standard,

now COA, NMR, HPLC, MS is ok.

REFERENCE:

1: Lesueur P, Chevalier F, El-Habr EA, Junier MP, Chneiweiss H, Castera L, Müller E, Stefan D, Saintigny Y. Radiosensitization Effect of Talazoparib, a Parp Inhibitor, on Glioblastoma Stem Cells Exposed to Low and High Linear Energy Transfer Radiation. Sci Rep. 2018 Feb 26;8(1):3664. doi: 10.1038/s41598-018-22022-4. PubMed PMID: 29483558; PubMed Central PMCID: PMC5826933.

2: Correction: Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. Clin Cancer Res. 2018 Feb 15;24(4):985. doi: 10.1158/1078-0432.CCR-17-3661. PubMed PMID: 29449416.

3: Talazoparib Bests Chemo for Breast Cancer. Cancer Discov. 2018 Feb;8(2):OF3. doi: 10.1158/2159-8290.CD-NB2017-180. Epub 2017 Dec 14. PubMed PMID: 29242215.

4: Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR, Adrada BE, Moulder SL, Barcenas CH, Valero V, Gomez JS, Mittendorf EA, Thompson A, Helgason T, Mills GB, Piwnica-Worms H, Arun BK. A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity. NPJ Breast Cancer. 2017 Dec 6;3:49. doi: 10.1038/s41523-017-0052-4. eCollection 2017. PubMed PMID: 29238749; PubMed Central PMCID: PMC5719044.

5: Belz JE, Kumar R, Baldwin P, Ojo NC, Leal AS, Royce DB, Zhang D, van de Ven AL, Liby KT, Sridhar S. Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer. Theranostics. 2017 Sep 26;7(17):4340-4349. doi: 10.7150/thno.18563. eCollection 2017. PubMed PMID: 29158830; PubMed Central PMCID: PMC5695017.

6: Kizilbash SH, Gupta SK, Chang K, Kawashima R, Parrish KE, Carlson BL, Bakken KK, Mladek AC, Schroeder MA, Decker PA, Kitange GJ, Shen Y, Feng Y, Protter AA, Elmquist WF, Sarkaria JN. Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma. Mol Cancer Ther. 2017 Dec;16(12):2735-2746. doi: 10.1158/1535-7163.MCT-17-0365. Epub 2017 Sep 25. PubMed PMID: 28947502; PubMed Central PMCID: PMC5716902.

7: Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser M, Kelley RK, Maktabi T, Thomas S, Munster PN. Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. Clin Cancer Res. 2017 Nov 1;23(21):6400-6410. doi: 10.1158/1078-0432.CCR-17-0703. Epub 2017 Aug 8. Erratum in: Clin Cancer Res. 2018 Feb 15;24(4):985. PubMed PMID: 28790114.

8: Hidau MK, Kolluru S, Palakurthi S. Development and validation of a high-performance liquid chromatography method for the quantification of talazoparib in rat plasma: Application to plasma protein binding studies. Biomed Chromatogr. 2018 Feb;32(2). doi: 10.1002/bmc.4046. Epub 2017 Aug 15. PubMed PMID: 28677821.

9: de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, Henshaw JW, Herriott A, Patterson M, Curtin NJ, Byers LA, Wainberg ZA. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. Cancer Discov. 2017 Jun;7(6):620-629. doi: 10.1158/2159-8290.CD-16-1250. Epub 2017 Feb 27. PubMed PMID: 28242752; PubMed Central PMCID: PMC5905335.

10: Correction: Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program. Clin Cancer Res. 2017 Feb 15;23(4):1118-1119. doi: 10.1158/1078-0432.CCR-16-2920. PubMed PMID: 28211356.

11: Engert F, Kovac M, Baumhoer D, Nathrath M, Fulda S. Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics. Oncotarget. 2017 Jul 25;8(30):48794-48806. doi: 10.18632/oncotarget.10720. PubMed PMID: 27447864; PubMed Central PMCID: PMC5564725.

12: Wang B, Chu D, Feng Y, Shen Y, Aoyagi-Scharber M, Post LE. Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-te trahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent. J Med Chem. 2016 Jan 14;59(1):335-57. doi: 10.1021/acs.jmedchem.5b01498. Epub 2015 Dec 23. PubMed PMID: 26652717.

13: Herriott A, Tudhope SJ, Junge G, Rodrigues N, Patterson MJ, Woodhouse L, Lunec J, Hunter JE, Mulligan EA, Cole M, Allinson LM, Wallis JP, Marshall S, Wang E, Curtin NJ, Willmore E. PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia. Oncotarget. 2015 Dec 22;6(41):43978-91. doi: 10.18632/oncotarget.6287. PubMed PMID: 26539646; PubMed Central PMCID: PMC4791280.

14: Smith MA, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Carol H, Lock RB, Keir ST, Maris JM, Billups CA, Lyalin D, Kurmasheva RT, Houghton PJ. Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Clin Cancer Res. 2015 Feb 15;21(4):819-32. doi: 10.1158/1078-0432.CCR-14-2572. Epub 2014 Dec 10. Erratum in: Clin Cancer Res. 2017 Feb 15;23 (4):1118-1119. PubMed PMID: 25500058; PubMed Central PMCID: PMC4587665.

Biggest Manufacturer，Idasanutlin KK-20（1229705-06-9） and Intermediates.

EOS med chem is the only manufacturer that provides excellent quality chemistry products and services at affordable rates. The experts working here are highly trained to handle these chemicals used in the creation of medicines used for treating various life-threatening diseases. We are into the manufacturing of chemical products after doing a deep research for the same.

EOS team of experts holds the work experience of more than ten years, and therefore we can assure you about the quality and superiority of the products and services we offer to all our valued clients around the globe. At present, this organization is listed among the most leading pharmaceutical suppliers around the world. We always supply products keeping the affordability in mind.

  2018 Korea CPHI, C30

EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
WEB: www.eosmedchem.com
EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com  TEL: 0086-531-69905422
GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.

1.

Idasanutlin KK-20, CAS#1229705-06-9, HNMR, HPLC 99%+, LCMS, COA, MSDS and ROS, more than 54KG in stock, pls check:

Name:Idasanutlin KK-20

CAS#: 1229705-06-9

Formula: C31H29Cl2F2N3O4 

Exact Mass: 615.15032 

Molecular Weight: 616.48247 

Elemental Analysis: C, 60.40; H, 4.74; Cl, 11.50; F, 6.16; N, 6.82; O, 10.38

Appearance: white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

2. 

Idasanutlin KK-20Intermediates:

1. Idasanutlin KK-20 Intermediate:3-(3-Chloro-2-fluorophenyl)-2-(4-chloro-2-fluorophenyl)acrylonitrile,

Cas#1219086-87-9

We have more than 65kg in stock, assay 99% in GMP plant, C-GMP standard, 

now COA, NMR, HPLC, MS is ok.

2. Idasanutlin KK-20 Intermediate:Ethyl 4-(2-((3,3-dimethylbutylidene)amino)acetamido)-3-methoxybenzoate

Cas#2034194-92-6

We have more than 68kg in stock, assay 99% in GMP plant, C-GMP standard, 

now COA, NMR, HPLC, MS is ok.

Reference：

1: Ding Q, Zhang Z, Liu JJ, Jiang N, Zhang J, Ross TM, Chu XJ, Bartkovitz D, Podlaski F, Janson C, Tovar C, Filipovic ZM, Higgins B, Glenn K, Packman K, Vassilev LT, Graves B. Discovery of RG7388, a Potent and Selective p53-MDM2 Inhibitor in Clinical Development. J Med Chem. 2013, 56 (14), 5979–5983.

PubMed PMID: 23808545.